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Purpose: High activity of the intracellular phosphatidylinositol-3 kinase (PI3K) pathway is common in breast cancer.
Here, we explore differences in expression of important PI3K pathway regulators: the activator, phosphatidylinositol-3-
kinase catalytic subunit alpha (PIK3CA), and the tumour suppressor, phosphatase and tensin homolog (PTEN), in breast
carcinoma tissue and normal breast tissue. Furthermore, we examine whether expression of PIK3CA and PTEN mRNA
and occurrence of PIK3CA mutations are associated with lymph node metastases in patients with primary breast cancer.
Methods: Paired tissue samples of breast carcinoma and normal breast tissue were obtained from 175 breast cancer
patients at the time of primary surgery, of these 105 patients were lymph node positive. Expression of PIK3CA and
PTEN mRNA was quantified with Quantitative Real Time PCR. Somatic mutations in exon 9 and exon 20 of the PIK3CA
gene were identified by genotyping.
Results: Both PIK3CA and PTEN mRNA expression was significantly increased in breast carcinoma tissue compared to
normal breast tissue (p = 2 × 10-11) and (p < 0.001), respectively. PIK3CA mutations were present in 68 out of 175
patients (39%), but were not associated with PIK3CA expression (p = 0.59). Expression of PIK3CA and PTEN mRNA, and
PIK3CA mutations in breast carcinomas were not associated with presence of lymph node metastases.
Conclusions: The expression of PTEN and PIK3CA mRNA is increased in breast carcinoma tissue compared to normal
breast tissue, and PIK3CA mutations are frequent in primary breast carcinoma, however these factors were not
associated with lymph node metastases.
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The phosphatidylinositol-3 kinase (PI3K) intracellular path-
way promotes cell survival, proliferation and growth
(Engelman et al. 2006). It is one of the most commonly al-
tered pathways in human cancers (Samuels et al. 2004; Cully
et al. 2006) and plays a major role in breast cancer develop-
ment and progression.(Campbell et al. 2004; Bachman et al.
2004; McAuliffe et al. 2010; Boyault et al. 2012).
The PI3K is composed of two subunits: An 85 kDa
regulatory subunit and an 110 kDa catalytic subunit.
The catalytic subunit PIK3CA is encoded by the PIK3CA
gene, and is the main regulator of PI3K activation. Acti-
vation of PI3K leads to downstream signalling through a* Correspondence: boesoe@rm.dk
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in any medium, provided the original work is pseries of serine/threonine kinases, resulting in increased
cell survival and proliferation (Engelman et al. 2006).
Another key regulator of the PI3K pathway is the lipid
phosphatase and tensin homolog (PTEN) encoded by
the PTEN gene. PTEN inhibits activation of the PI3K
protein (Cully et al. 2006).
Somatic mutations in the PIK3CA gene often result in
increased activity of PIK3CA, and the gene is thus
regarded as a transforming oncogene (Boyault et al.
2012). PIK3CA mutations are reported in 18%–40% of
breast cancers (Kalinsky et al. 2009; Cizkova et al. 2012;
Harle et al. 2013), most frequently in exon 9 and 20
(Campbell et al. 2004; Samuels et al. 2004).
The association between PIK3CA mutations and lymph
node metastases is still unclear. Saal et al. reported ans an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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metastases (Saal et al. 2005), and this was supported by a
large study which reported an association between expres-
sion of the PIK3CA and lymph node metastases
(Aleskandarany et al. 2010). However, results are conflicting
as other studies have failed to find such associations
(Buttitta et al. 2006; Maruyama et al. 2007; Cizkova et al.
2012). In addition, the study by Kalinsky et al. (2009)
showed an association between PIK3CA mutations and ab-
sence of lymph node metastases.
In this study, we examine the mRNA expression of the
key regulators of the PI3K signalling pathway, PIK3CA,
PTEN, and the occurrence of PIK3CA mutations in
breast cancer and corresponding normal tissue from pa-
tients with primary breast cancer, and we relate the re-
sults to the presence of lymph node metastases.
Materials and methods
Study population and samples
This study from 2008–2009 includes 175 women with pri-
mary breast cancer. Of these, 105 were lymph node posi-
tive. Inclusion criteria were age >18 years and an operable
primary breast cancer. Patients previously treated with
neoadjuvant therapy were excluded. Permission from the
Danish Research Ethics Committee (N-20070047) and the
Danish Data Protection Agency (2011-41-6930) was
obtained in 2007 and 2011 respectively. All patients signed
informed consent. The inclusion of patients took place
during the first round of breast cancer screening in
Denmark and consequently the percentage of patients
with lymph node metastases is higher than expected.
Tissue samples from the breast carcinoma and the
normal breast tissue were obtained from each patient atFigure 1 Flowchart illustrating the materials and the analyses perform
** Data are shown in Figures 2 and 3. *** Data are shown in Tables 1, 2 anthe time of primary surgery. Due to insufficient amount
or quality of RNA, 26 patients were excluded from the
paired analyses (Figure 1), which therefore included only
149 patients. All tissue samples were immediately frozen
and stored at −80°C.
Extraction of mRNA and preparation of cDNA
Total RNA was extracted from all tissue samples
employing the total RNA kit from Qiagen©, (Qiagen,
Hilden, Germany, www.qiagen.com) according to the
manufacturer’s instructions.
cDNA was synthesized from 1 μg total RNA in a 20 μl
reaction mix including 50 μmol/l Oligo(dT), reverse tran-
scriptase (50 units/μl), RNase inhibitors (20 units/μl), 0.4
mmol/l of each dNTP, 1 × PCR buffer, and 25 mmol/l
MgCL2. All reagents were from Applied Biosystems® (Ap-
plied Biosystems Inc., CA, USA). Reverse transcription
was performed on the Perkin-Elmer GeneAmp® PCR Sys-
tem 9600 Thermal Cycler (PerkinElmer Inc., MA, USA)
with the profile: 42°C for 30 minutes, 99°C for 5 minutes
and 4°C until samples had cooled. cDNA was stored
at −20°C until further use.
Quantification of PIK3CA, PTEN and HMBS mRNA
Quantitative Real Time PCR (qPCR) was used to quan-
tify PIK3CA, PTEN and hydroxy-methyl-bilane synthase
(HMBS) cDNA with the LightCycler® 480 (LC480) Real-
Time PCR System from Roche (Roche Applied Science,
Mannheim, Germany, www.roche-applied-science.com).
HMBS was used to control for variations in RNA con-
centration and integrity and was found to be the best
suited household gene when compared to β-Actin
(ACTB), glyceraldehyde-3-phosphate dehydrogenaseed. * Exclusion was due to insufficient amount or quality of RNA.
d 3.
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monooxygenase activation protein zeta polypeptide
(YWHAZ) and beta-2-microglobulin (B2M) according
to the Normfinder method (Andersen et al., 2004). The
reaction mix consisted of 5 μl SYBR® Green I Master
Mix Buffer (SYBR® Green RT-PCR Reagents Kit, Roche,
Mannheim, Germany), 0.5 pmol forward and reverse
primers (Eurofins MWG Synthesis GmbH, Ebersberg,
Germany), 1 μl cDNA and H20 to a final volume of 10
μl. The primers were designed to let the PCR product
span intron sequences in order to avoid DNA contamin-
ation. Primer sequences and accession numbers are
listed in Additional file 1: Table S1. qPCR was performed
with the following profile: 95°C for 10 min and a total
number of 50 cycles with an annealing temperature of
66°C when using PIK3CA primers, 64°C when using
PTEN primers and 59°C when using the HMBS primers.
However all products were detected before cycle 32. Fol-
lowing amplification, a melting curve was obtained to
provide evidence for a single reaction product. The
Roche® LC480 Software Version 1.5.0.39 (Roche Applied
Science, Mannheim Germany) was used for quantifica-
tion and melting temperature determination. A no-
template control (nuclease-free water instead of RNA)
was included in each run. Serial dilutions of RNA from
the breast cancer cell line MDA MB (from ATCC) were
used as calibrators.
Analysis of PIK3CA mutations
We genotyped the PIK3CA gene at exon 9 and exon 20
where > 90% of all PIK3CA mutations are clustered
(Campbell et al. 2004; Samuels et al. 2004). We used the
PI3K Mutation Test Kit from Qiagen© (Qiagen, Hilden,
Germany, www.qiagen.com), which contained one con-
trol assay and three mutations assays to be run in a
qPCR assay. The qPCR was performed on cDNA from
all breast carcinoma samples using the Roche® LC 480
instrument.
Pathological examination
All tissue samples were examined by specialists in breast
pathology at the Institute of Pathology, Aalborg Univer-
sity Hospital. Tumour size and histological type (invasive
ductal; invasive lobular; other types) were evaluated
according to the Danish Breast Cancer (DBCG) guide-
lines. Oestrogen receptor (ER) status was determined by
immunohistochemistry (IHC). Human epidermal growth
factor receptor 2 (HER2) status was determined by IHC
and fluorescence in situ hybridization (FISH).
Statistical analysis
We used a paired t-test of log-transformed concentra-
tions of PIK3CA and PTEN mRNA to compare expres-
sion in breast carcinoma tissue and normal breast tissue.To test for associations between PIK3CA mutations
and/or expression of PIK3CA and/or PTEN and lymph
node metastases, we used four different approaches:
First, we log-transformed PIK3CA and PTEN levels and
used an unpaired t-test to compare expression of
PIK3CA and PTEN in breast carcinoma tissue from pa-
tients with and without lymph node metastases and to
compare levels of PIK3CA expression in patients with
and without PIK3CA mutations. Second, patients were
divided in two groups using the median value of either
PIK3CA or PTEN as cut-off. We used a chi2 test to test
whether elevated expression of PIK3CA or PTEN in
breast carcinoma associated with lymph node metasta-
ses. We repeated analyses with patients stratified
according to PIK3CA mutations in breast carcinoma tis-
sue (one or more mutations vs. no mutations,“wild-
type”). Third, patients were stratified into groups
according to their number of risk factors. Risk factors
were defined as PIK3CA expression above median,
PTEN expression below median, and PIK3CA mutations.
We used a Cuzick’s extension of the Wilcoxon rank sum
test to calculate p-trend across groups. Finally, we calcu-
lated risk of lymph node metastases based on the binary
variables of PIK3CA and PTEN expression and PIK3CA
mutations using two different logistic regression models
to calculate odds ratios (ORs) with 95% confidence in-
tervals. The models were 1) unadjusted and 2) adjusted
for age at surgery, tumour size, tumour histology, ER
status, and HER2 status.
Stata 12.0 (StataCorp LP, College Station, TX, USA)
was used for all statistical analyses and GraphPad Prism
4.03 (GraphPad Software Inc., CA, USA) was used for
depicting the results.
Results
The clinical and pathological characteristics of all 175
patients are listed in Table 1.
PIK3CA and PTEN mRNA expression in breast carcinoma
and in normal breast tissue in 149 patients
PIK3CA mRNA expression in breast carcinoma tissue was
significantly higher than in normal breast tissue (p = 2 ×
10-11), with a median value of 56 for the PIK3CA/HMBS
ratio in breast carcinoma tissue compared to 23 PIK3CA/
HMBS in normal breast tissue (Figure 2) PIK3CA mRNA
expression was increased in tumour tissue in 114 out of
149 patients (76%).
Unexpectedly, PTEN mRNA expression in breast car-
cinoma tissue was significantly higher than in normal
breast tissue (p = 2 × 10-11), with a median value of 24
for the PTEN/HMBS ratio in breast carcinoma tissue
compared to 12 PTEN/HMBS in the normal breast tis-
sue. PTEN mRNA expression was reduced in tumour
tissue in only 31 out of 149 patients (20%). When we
Table 1 Clinical pathological characteristics of the 175 study participants in relation to levels of PIK3CA-, PTEN mRNA
expression and PIK3CA mutations in the primary breast carcinoma
PIK3CA expression (n = 175) PTEN expression (n = 175) PIK3CA mutations (n = 175)
Low PIK3CA High PIK3CA Low PTEN High PTEN Wildtype Mutations
Number, N (%) 87 (50) 88 (50) 87 (50) 88 (50) 107 (61) 68 (39)
Age, years median (range) 64 (38–85) 65 (32–83) 64 (36–85) 63 (32–82) 64 (32–85) 63 (38–83)
Tumour size, mm, median (range) 21 (6–60) 18 (6–51) 21 (6–60) 18 (6–50) 19 (6–55) 19 (7–60)
Oestrogen receptor status, N (%)
Positive 74 (85) 79 (90) 74 (85) 79 (90) 92 (86) 61 (90)
Negative 13 (15) 9 (10) 13 (15) 9 (10) 15 (14) 7 (10)
HER2 status, N (%)
Normal expression 65 (74) 69 (78) 59 (68) 75 (85) 81 (76) 53 (78)
Overexpression 10 (11) 11 (13) 11 (13) 10 (11) 13 (12) 8 (12)
Unknown 12 (14) 8 (9) 17 (19) 3 (3) 13 (12) 7 (10)
Histology, N (%)
Invasive ductal carcinoma 68 (78) 70 (80) 71 (82) 67 (76) 88 (82) 50 (74)
Invasive lobular carcinoma 10 (11) 15 (17) 8 (9) 17 (19) 14 (13) 11 (16)
Other 9 (10) 3 (3) 8 (9) 4 (5) 5 (5) 7 (10)
Low PIK3CA expression is PIK3CA expression ≤ 50 (median) high expressions is values above 50. Low PTEN expression is PTEN expression ≤ 23. (median). High
values are values above 23 Wildtype = no PIK3CA mutations. HER2 human epidermal growth factor receptor 2.HER2 overexpression is score 2+ and 3+ after
FISH amplification.
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ferent strata of the study population: By oestrogen re-
ceptor status, HER2 status, and by tumour histology,
results were similar (Additional file 1: Table S2).
PIK3CA, PTEN mRNA expression and PIK3CA mutations in
relation to lymph node metastases
Levels of PIK3CA and PTEN expression in breast car-
cinoma tissue were similar in patients with and without
lymph node metastases (p = 0.72 and p = 0.48) (Figure 3)
There was no association between elevated PIK3CA ex-
pression and lymph node metastases (p = 0.71) or be-
tween reduced PTEN expression and lymph node
metastases (p = 0.32) (Table 2).
Mutations in the PIK3CA gene were present in 68 (39%)
of 175 patients. The most frequent location was in exon 20Figure 2 PIK3CA and PTEN mRNA expression in paired normal and br
positive and n = 54 lymph node negative).located at H1074R (54%) and less frequent in exon 9 at
E545K/D (31%) and E542K (15%). Patients carrying PIK3CA
mutations had higher PIK3CA expression (median of 62 vs.
47), but this was not significant (p = 0.59) (Additional file 1:
Table S3). There was no association between PIK3CA muta-
tions and lymph node metastases (p = 0.80) (Table 2).
We stratified the patients according to number of risk
factors (PIK3CA expression above median, PTEN ex-
pression below median, and presence of PIK3CA muta-
tions) and found that 13 (7%) had no risk factors, 91
(52%) had one risk factor, 61 (35%) had two risk factors,
and 10 (6%) had three risk factors. We did not find an
increased risk of lymph node metastases across groups
(p-trend = 0.543) (Table 3).
Finally, the unadjusted odds ratio (OR) was 1.12 (95%
confidence interval (CI) 0.61-2.05) for patients witheast carcinoma tissue from 149 patients (n = 95 lymph node
Figure 3 PIK3CA and PTEN mRNA expression in breast carcinoma tissue from 149 patients in relation to lymph node metastases,
(n = 95 lymph node positive and n = 54 lymph node negative).
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tients with PIK3CA expression below or at this level.
After multifactorial adjustment for age, tumour size,
histology, ER status, and HER2 status, the OR was 1.36
(0.71-2.59) (Additional file 1: Table S4). The correspond-
ing ORs were 0.73 (0.40-1.35) and 0.57 (0.29-1.11) for
patients with PTEN expression below or at the median
level compared to patients with PTEN expression above
this level, and 0.92 (0.49-1.72) and 0.96 (0.50-1.82) for
patients with PIK3CA mutations compared to patients
without.
Discussion
In this study, we examined important regulators of the
PI3K pathway in primary breast carcinoma and normal
breast tissue to test whether an increased expression of
the PI3K pathway activator, PIK3CA, a reduced expres-
sion of the tumour suppressor, PTEN, and the presence
of PIK3CA mutations in breast carcinoma tissue are as-
sociated with lymph node metastases.
While most breast cancer studies examined the role of
the PIK3CA mutations, less attention has been given to
PIK3CA expression. To our knowledge, no other study
has examined the PIK3CA expression in both breast car-
cinoma tissue and corresponding normal breast tissue.
Our data showed significantly higher PIK3CA expressionTable 2 Lymph-node status of the 175 study participants in r
PIK3CA mutations in the primary breast carcinoma
PIK3CA expression
Low PIK3CA High PIK3CA
Number, N (%) 87 (50) 88 (50)
Lymph node status, N (%)
No metastases 36 (41) 34 (39)
Metastases 51 (59) 54 (61)
p = 0.71
Low PIK3CA expression is PIK3CA expression ≤ 50.60 (median). Low PTEN expression
Wildtype = no PIK3CA mutations. HER2 human epidermal growth factor receptor 2.in breast carcinoma tissue than in normal breast tissue,
a consistent finding even after stratifying for oestrogen
receptor and HER2 receptor status as well as for tumour
histology. This finding supports the hypothesis of an ac-
tivated PI3K pathway in cancer cells, and it further sup-
ports the analysis of mRNA expression for detecting
intracellular protein levels as an addition to direct pro-
tein measurements using IHC. Further studies are
needed to explore the direct relation between expression
of PIK3CA on mRNA and protein levels.
We did, however, fail to find association between PIK3CA
expression and lymph node metastases. Our results conflict
with a study of 1394 patients with primary operable breast
cancer. The authors used IHC for measurement of PIK3CA
and reported that elevated PIK3CA expression associated
with a poor prognosis including lymph node metastases
(Aleskandarany et al. 2010). Further studies are needed in
order to unravel this discrepancy.
Unexpectedly, we did not find a decreased PTEN
mRNA expression in tumour tissue. Our data showed a
low PTEN mRNA expression in breast carcinoma tissue
compared to the expression in normal breast tissue in
only 20% of our paired cohort of 149 patients. In a study
of 85 primary breast cancer patients using IHC for the
detection of PTEN, a reduced or absent PTEN expres-
sion in breast carcinoma tissue compared to normalelation to levels of PIK3CA-, PTEN mRNA expression and
PTEN expression PIK3CA mutations
Low PTEN High PTEN Wildtype Mutations
87 (50) 88 (50) 107 (61) 68 (39)
38 (44) 32 (36) 42 (39) 28 (41)
49 (56) 56 (64) 65 (61) 40 (59)
p = 0.32 p = 0.80
is PTEN expression ≤ 22.98 (median).
Table 3 Lymph-node status of the 175 study participants with primary breast cancer in relation to one or more
potential risk factors
No. of potential risk factors
0 1 2 3 Total p-trend
Number, N (%) 13 (7) 91 (52) 61 (35) 10 (6) 175 (100)
Lymph node status, N (%)
No metastases 5 (38) 36 (40) 23 (38) 6 (60) 70 (40) 0.543
Metastases 8 (62) 55 (60) 38 (62) 4 (40) 105 (60)
Potential risk factors are: PIK3CA expression > 50.60 (median), PTEN expression ≤ 22.98 (median), and PIK3CA mutations.
Palimaru et al. SpringerPlus 2013, 2:464 Page 6 of 7
http://www.springerplus.com/content/2/1/464tissue was found in only 33% of the patients (Engin et al.
2006). Five other studies also detected low PTEN ex-
pression in primary breast carcinomas with IHC (Perren
et al. 1999; Depowski et al. 2001; Lin et al. 2003; Lee
et al. 2004; Gonzalez-Angulo et al. 2011), but these stud-
ies did not examine PTEN expression in the correspond-
ing normal breast tissue.
We did not find any association between reduced
PTEN and positive lymph node status. Previous results
have been conflicting. The study mentioned above with
85 patients reported no association (Engin et al. 2006),
while two other studies found an association between re-
duced PTEN in tumour tissue and lymph node metasta-
ses (Depowski et al. 2001; Lee et al. 2004). However,
compared to our study population, the patients in these
studies had a larger mean tumour size (Lee et al. 2004)
and a more advanced cancer (tumour stages III and IV)
(Depowski et al. 2001).
Finally, we found that PIK3CA mutations are frequent
in primary breast cancer but were not associated with
lymph node metastases. Of our patients, 39% had PIK3CA
mutations, which is similar to the prevalence of 18%–40%
reported in previous studies (Campbell et al. 2004;
Bachman et al. 2004; Saal et al. 2005; Cully et al. 2006;
Boyault et al. 2012). In line with previous studies, most
mutations were located in exon 20 (Bachman et al. 2004;
Saal et al. 2005; Maruyama et al. 2007; Kalinsky et al.
2009) and not associated with lymph node metastases
(Campbell et al. 2004; Buttitta et al. 2006; Maruyama et al.
2007; Kalinsky et al. 2009; Boyault et al. 2012; Cizkova
et al. 2012). However, one study of 160 Swedish primary
breast cancer patients reported an association between
PIK3CA mutations and lymph node metastases. Com-
pared to our study, the prevalence of human epidermal
growth factor receptor 2 (HER2) positive patients was
twice as high as in the Swedish study population.
An important strength of our study is the paired ma-
terial, both breast carcinoma tissue and normal breast
tissue. Second, all samples were collected at the time of
surgery before the patients received other treatments (e.
g. neoadjuvant therapy), which might influence the regu-
lation and activity of the PI3K signalling pathway
(Gonzalez-Angulo et al. 2011). Third, while most otherstudies used IHC (Perren et al. 1999; Depowski et al.
2001; Lin et al. 2003; Lee et al. 2004; Engin et al. 2006;
Aleskandarany et al. 2010; Gonzalez-Angulo et al. 2011),
we used qPCR to determine expression of PTEN and
PIK3CA, which enables quantification relative to a
household gene and is not biased by subjective factors
such as the experience of the assessor (Tvrdik et al.
2012; Mendoza et al. 2013).
A potential limitation of our study is the limited num-
ber of patients. Furthermore, almost 15% of all paired
tissue samples were unavailable due to insufficient
amount or quality of RNA after our qPCR analysis. Be-
cause the loss of data was most likely completely at ran-
dom, we do not expect it to bias our results. Another
potential limitation is that we did not have sufficient
amount of tissue to measure protein levels of PIK3CA
and PTEN and therefore we used the less tissue
consuming mRNA expression technique, assuming that
mRNA expression corresponds to the protein levels.
Conclusions
In conclusion, we found significantly increased PIK3CA ex-
pression in breast carcinoma tissue compared to normal
breast tissue. Unexpectedly, we also found increased PTEN
expression in breast carcinoma tissue. An overactive PI3K
pathway caused by increased PIK3CA expression, reduced
PTEN expression, and PIK3CA mutations were not found
to be associated with lymph node metastases.
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